03:02 , Feb 2, 2018 |  BC Innovations  |  Product R&D

It’s the assay...

Genentech and Xenon have reported that the key to finding a selective Nav1.7 blocker is devising a better screen, not using a bigger compound library. By retooling a commonly used assay, the partners identified a...
07:00 , Oct 5, 2015 |  BC Week In Review  |  Company News

Chromocell, Astellas deal

Chromocell granted Astellas exclusive, worldwide rights to develop and commercialize the biotech’s CC8464 and backup candidates for pain. Chromocell plans to submit an IND for CC8464 in early 2016 and to lead development of...
01:02 , Oct 1, 2015 |  BC Extra  |  Company News

Astellas gains rights to Chromocell pain program

Astellas Pharma Inc. (Tokyo:4503) gained exclusive, worldwide rights to commercialize CC8464 and backup candidates from Chromocell Corp. (North Brunswick, N.J.) in pain indications. Chromocell plans to submit an IND for CC8464 in early 2016. The...